HHS has awarded $8.3 million to the API Innovation Center to expand domestic manufacturing of two essential hospital medicines: metoprolol and propofol.
The funding will support end-to-end U.S. production of metoprolol for the first time in decades, according to a March 24 news release from the Administration for Strategic Preparedness and Response. With roughly 90% of cardiovascular drugs used in the U.S. sourced from India or China, the investment aims to reduce reliance on foreign suppliers and strengthen the domestic supply chain for medicines used in cardiovascular, surgical and intensive care settings.
The latest award brings total federal investment in the API Innovation Center to more than $22 million. It follows a $14 million grant in September 2024 to support domestic production of three other critical APIs.
The funds were awarded through the Biopharmaceutical Manufacturing Preparedness Consortium.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
